You are here » Home » Companies » Company Overview » Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Ltd.

BSE: 524396 Sector: Health care
NSE: BIOFILCHEM ISIN Code: INE829A01014
BSE LIVE 15:00 | 02 Dec 7.69 -0.40
(-4.94%)
OPEN

8.49

HIGH

8.49

LOW

7.69

NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 8.49
PREVIOUS CLOSE 8.09
VOLUME 3299
52-Week high 12.00
52-Week low 6.04
P/E 13.26
Mkt Cap.(Rs cr) 12.51
Buy Price 0.00
Buy Qty 0.00
Sell Price 8.49
Sell Qty 1190.00
OPEN 8.49
CLOSE 8.09
VOLUME 3299
52-Week high 12.00
52-Week low 6.04
P/E 13.26
Mkt Cap.(Rs cr) 12.51
Buy Price 0.00
Buy Qty 0.00
Sell Price 8.49
Sell Qty 1190.00

Biofil Chemicals & Pharmaceuticals Ltd. (BIOFILCHEM) - Company History

Biofil Chemicals & Pharmaceuticals (BCPL) was incorporated as a private limited company on 4 Jan.'85 for manufacture of pharmaceutical products and it was converted into a public limited company on 7 May '92. It was promoted by the Systematix group and Ramesh Shah of the Cyano group. Ramesh Shah is the chairman and managing director and Anand Kumar Sethiya is the managing director. In Feb.'96, the company had come out with a rights-cum-public issue at a premium of Rs 7.50 and at a premium of Rs 12.50 respectively, both aggregating Rs 23.21 cr, to part-finance its expansion and diversification into bulk drugs and pharmaceutical formulations. The company currently manufactures pharmaceutical formulations like injections, capsules, eye-drops and dry syrups at its plant located in Indore. BCPL's new unit is being set up at Pithampur in Madhya Pradesh at a project cost of Rs 39.75 cr and will manufacture bulk drugs like astemizole, cefaclor, pentazocine, cefazolin sodium and cefotoxime sodium. It is also setting up a R&D centre which will include a pilot plant for bulk drugs and separate sections for formulations development and will house modern analytical instruments. During the year 1999-2000, the company had achieved a turnover of Rs.1164.03 lakhs.

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard